Drug Trial Radar · NCT06699108
Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy
Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Dec 13, 2024
Primary completion
Dec 1, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 study to evaluate the efficacy and safety of VGR-R01 in subjects with Bietti Crystalline Dystrophy. This is a multicenter, randomized controlled study which will enroll 45 subjects.
Conditions
- Bietti Crystalline Dystrophy
- Inherited Retinal Diseases
Interventions
VGR-R01Drug
Subretinal injection of VGR-R01 (0.1 mL)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with change in BCVA in the study eyes of BCD subjects as assessed by ETDRSTime frame: Baseline up to Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Vitalgen Biopharma Co.,Ltd.
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.